Sentis Lung Cancer Tissue Outsource Genetech at Chughtai Lab

Sentis Lung Cancer Tissue Outsource Genetech at Chughtai Lab

The Sentis Lung Cancer Tissue Outsource Genetech test at Chughtai Lab represents a significant advancement in personalized oncology and precision medicine for patients in Pakistan. Lung cancer remains one of the most prevalent and clinically challenging malignancies globally and locally. Historically, treatment decisions were based almost entirely on the histological classification of the tumor, such as distinguishing between small cell lung cancer and non-small cell lung cancer (NSCLC). However, modern oncology recognizes that lung tumors are highly heterogeneous at the molecular level. The Sentis Lung Cancer Tissue Outsource Genetech panel is a specialized molecular pathology investigation designed to analyze the genomic profile of lung cancer tissue. By identifying specific somatic mutations, fusions, and amplifications within the tumor DNA and RNA, this test enables oncologists to transition from empirical chemotherapy to highly targeted, individualized therapeutic regimens.

This advanced diagnostic service is facilitated through Chughtai Lab, Pakistan’s premier diagnostic network, in collaboration with Genetech, a specialized molecular diagnostics laboratory. The test utilizes state-of-the-art molecular biology techniques, including Next-Generation Sequencing (NGS) and multiplex Polymerase Chain Reaction (PCR), to detect actionable driver mutations. The primary anatomical focus of this evaluation is the lung tumor tissue itself, typically obtained via a core needle biopsy, bronchoscopic biopsy, or surgical resection. By analyzing the genetic alterations within the tumor cells, the test provides critical insights into the biological pathways driving oncogenesis. This molecular characterization is essential for identifying patients who are likely to benefit from specific tyrosine kinase inhibitors (TKIs) and other targeted therapies, thereby optimizing treatment efficacy while minimizing unnecessary toxicity from ineffective treatments.

Clinical Importance and Diagnostic Value

The clinical utility of the Sentis Lung Cancer Tissue Outsource Genetech test lies in its ability to map the unique genetic signature of a patient’s tumor. In non-small cell lung cancer, particularly adenocarcinoma, specific driver mutations occur in well-characterized oncogenes. Identifying these mutations is no longer optional; it is a standard-of-care recommendation by international guidelines, including the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO). The diagnostic value of this panel is profound, as it directly influences first-line therapy selection. For instance, patients harboring specific epidermal growth factor receptor (EGFR) mutations respond exceptionally well to EGFR inhibitors, whereas those with anaplastic lymphoma kinase (ALK) or ROS1 rearrangements benefit from targeted ALK/ROS1 inhibitors. Conversely, identifying certain mutations, such as KRAS, can provide valuable prognostic information and guide alternative therapeutic strategies. By offering this outsourced genetic testing, Chughtai Lab ensures that patients across Pakistan have access to international-standard molecular diagnostics that are crucial for modern cancer care.

Clinical Procedure: What to Expect

Patient Preparation

Because the Sentis Lung Cancer Tissue Outsource Genetech test is performed on pre-collected tissue specimens (formalin-fixed paraffin-embedded tissue blocks or unstained slides), there is no direct physical preparation required from the patient at the time of the laboratory order. However, the preparation phase is critical and involves the following clinical considerations:

• Tissue Specimen Retrieval: The patient or their healthcare provider must retrieve the formalin-fixed paraffin-embedded (FFPE) tissue block and the corresponding histopathology slides from the pathology department where the original biopsy or surgical resection was performed.
• Pathology Report Submission: A copy of the original histopathology report must accompany the tissue specimen. This report provides essential context regarding the tumor type, cellularity, and diagnosis.
• Specimen Adequacy Assessment: Before outsourcing the sample, a pathologist at Chughtai Lab reviews the slide to ensure there is sufficient tumor cellularity (ideally at least 20% to 30% tumor content) to yield adequate DNA and RNA for molecular analysis.
• Clinical History: Detailed clinical information, including the patient’s age, gender, smoking history, stage of disease, and previous oncology treatments, should be provided to assist in the clinical interpretation of the genetic findings.
• No Fasting Required: Since no new blood draw or invasive procedure is performed at the laboratory for this specific test, the patient does not need to fast or alter their daily medication schedule.

During the Procedure (Sample Submission and Processing)

The workflow for the Sentis Lung Cancer Tissue Outsource Genetech test is highly structured to maintain specimen integrity and ensure analytical accuracy:

• Specimen Intake: The FFPE block and slides are submitted to a designated Chughtai Lab collection center. Staff verify the labeling, patient identification, and documentation to prevent any pre-analytical errors.
• Cold Chain and Transport: The tissue specimen is packaged securely and transported under controlled temperature conditions to the specialized molecular testing facility at Genetech. Maintaining an optimal environment prevents degradation of the nucleic acids within the paraffin block.
• Nucleic Acid Extraction: At the molecular laboratory, tumor-rich areas are microdissected from the tissue sections. The paraffin is removed, and the cells are lysed to extract high-quality genomic DNA and total RNA.
• Library Preparation and Sequencing: The extracted genetic material undergoes library preparation, where specific genomic regions of interest (such as exons of EGFR, ALK, ROS1, KRAS, BRAF, MET, RET, and NTRK) are amplified and tagged. Next-Generation Sequencing (NGS) or multiplex PCR is then performed to read the genetic sequences.
• Bioinformatics Analysis: Advanced computational algorithms compare the patient’s tumor sequence against a standard human reference genome to identify pathogenic mutations, insertions, deletions, translocations, and copy number variations.
• Pathologist Review and Reporting: A molecular pathologist reviews the bioinformatic data, correlates the findings with current clinical databases and therapeutic guidelines, and generates a comprehensive report detailing the detected alterations and their therapeutic implications.

When is a Sentis Lung Cancer Tissue Outsource Genetech Performed?

Advanced Non-Small Cell Lung Cancer (NSCLC) Diagnosis

The primary clinical indication for performing the Sentis Lung Cancer Tissue Outsource Genetech test is the initial diagnosis of advanced, recurrent, or metastatic non-small cell lung cancer, particularly adenocarcinoma. In these advanced stages, surgical cure is often not possible, and systemic therapy is the mainstay of treatment. Identifying actionable mutations at this stage allows oncologists to prescribe highly effective oral targeted therapies as first-line treatment, which frequently yield superior response rates and progression-free survival compared to traditional cytotoxic chemotherapy.

Selection of Targeted Tyrosine Kinase Inhibitors (TKIs)

Physicians request this comprehensive molecular panel to determine if a patient is an eligible candidate for specific tyrosine kinase inhibitors. For example, the detection of an EGFR exon 19 deletion or L858R point mutation indicates high sensitivity to EGFR TKIs such as erlotinib, gefitinib, afatinib, or osimertinib. Similarly, identifying ALK or ROS1 fusions guides the use of inhibitors like crizotinib, alectinib, or brigatinib. Without this genetic blueprint, selecting these highly effective, personalized therapies is impossible.

Monitoring and Identifying Resistance Mutations

In patients who have previously responded well to targeted therapies but are now experiencing disease progression, this test is performed to identify secondary resistance mutations. A classic example is the development of the EGFR T790M mutation in patients progressing on first- or second-generation EGFR inhibitors. Detecting this specific resistance mutation is crucial, as it renders the tumor sensitive to third-generation EGFR inhibitors like osimertinib, thereby offering patients continued therapeutic options.

Inadequate Response to Standard Chemotherapy

When a lung cancer patient does not respond to standard empirical chemotherapy regimens, or experiences rapid disease progression, clinicians may order the Sentis genetic panel. Identifying a previously unknown driver mutation can completely redirect the clinical management plan, allowing the patient to transition from ineffective chemotherapy to a targeted agent that specifically addresses the molecular driver of their malignancy.

Personalized Oncology Treatment Planning

Oncologists utilize this comprehensive genetic profile to formulate a long-term, personalized treatment roadmap. Beyond identifying immediate therapeutic targets, the test can reveal prognostic markers or mutations that indicate resistance to certain drugs. This detailed molecular understanding helps clinicians avoid prescribing therapies that are unlikely to succeed, saving the patient from unnecessary side effects and financial burden while focusing resources on the most promising clinical pathways.

What Does a Sentis Lung Cancer Tissue Outsource Genetech Detect?

The Sentis Lung Cancer Tissue Outsource Genetech panel is designed to detect a wide array of clinically significant genetic alterations. These findings are critical for defining the molecular subtype of the lung tumor and guiding therapeutic interventions. The panel specifically evaluates:

• EGFR Exon 19 Deletions: Activating mutations that predict high sensitivity to first-, second-, and third-generation EGFR tyrosine kinase inhibitors.
• EGFR L858R Point Mutation: A common activating mutation in exon 21 associated with favorable response to EGFR-targeted therapies.
• EGFR T790M Resistance Mutation: A secondary mutation in exon 20 that mediates resistance to early-generation EGFR TKIs but is targetable by osimertinib.
• EGFR Exon 20 Insertions: Mutations generally associated with resistance to standard EGFR TKIs, requiring specific targeted agents or specialized treatment protocols.
• EML4-ALK Fusion Gene: A chromosomal translocation resulting in a constitutively active ALK fusion protein, indicating high sensitivity to ALK inhibitors.
• ROS1 Gene Rearrangements: Fusions involving the ROS1 gene (e.g., CD74-ROS1) that predict excellent response to ROS1-targeted tyrosine kinase inhibitors.
• KRAS G12C Mutation: A specific somatic mutation in the KRAS oncogene that can now be targeted by specialized KRAS G12C inhibitors.
• Other KRAS Mutations: Activating mutations in codons 12, 13, or 61 that generally indicate resistance to EGFR TKIs and are associated with specific prognostic outcomes.
• BRAF V600E Mutation: A point mutation in the BRAF gene that renders the tumor sensitive to combined BRAF and MEK inhibitor therapy.
• Non-V600E BRAF Mutations: Less common alterations in the BRAF gene that assist in prognostic stratification and clinical trial selection.
• MET Exon 14 Skipping Mutations: Splice-site alterations leading to MET activation, which can be treated with specific MET inhibitors.
• MET Gene Amplification: An increase in MET gene copy number, which can act as a primary driver or an acquired resistance mechanism to EGFR therapy.
• RET Gene Fusions: Chromosomal rearrangements involving the RET oncogene, indicating eligibility for selective RET inhibitors.
• NTRK1, NTRK2, and NTRK3 Fusions: Rare but highly actionable gene fusions that predict profound responses to TRK inhibitors regardless of tumor histology.
• HER2 (ERBB2) Mutations: Insertions or point mutations in the HER2 gene that guide the use of HER2-targeted antibody-drug conjugates.
• HER2 Gene Amplification: Increased copy numbers of the HER2 gene, providing additional therapeutic and prognostic insights.
• PIK3CA Mutations: Alterations in the phosphatidylinositol 3-kinase pathway that may contribute to drug resistance and tumor progression.
• AKT1 Mutations: Rare mutations within the AKT pathway that serve as potential therapeutic targets in clinical trials.
• MAP2K1 Mutations: Alterations in the MEK1 pathway that assist in comprehensive molecular profiling.
• Tumor Mutational Burden (TMB) Indicators: Genomic data that help estimate the overall mutation density, assisting in evaluating potential benefit from immunotherapy.

Turnaround Time and Report Access at Chughtai Lab

The Sentis Lung Cancer Tissue Outsource Genetech test is a highly complex molecular analysis involving multiple sophisticated laboratory steps, including tissue processing, nucleic acid extraction, high-throughput sequencing, and detailed bioinformatic interpretation. Consequently, the turnaround time for this specialized outsourced test is typically 10 to 14 working days from the date of sample receipt and verification at the main laboratory. This timeline ensures that every step of the quality control process is meticulously executed to guarantee the highest level of clinical accuracy.

Chughtai Lab offers seamless and convenient access to diagnostic reports. Once the molecular analysis is completed and verified by the consulting molecular pathologists, patients and their referring oncologists are immediately notified via SMS. The comprehensive PDF report can be viewed, downloaded, and printed directly from the official Chughtai Lab website using the unique patient ID and password provided on the booking receipt. Additionally, reports are accessible through the Chughtai Lab Mobile App, ensuring that critical diagnostic data is readily available to the clinical team to expedite treatment planning.

Sentis Lung Cancer Tissue Outsource Genetech Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
EGFR Gene Status	Wild-type (No mutation detected)	Exon 19 deletion, L858R mutation, T790M resistance mutation, or Exon 20 insertion
ALK Gene Rearrangement	Negative (No fusion detected)	Positive for EML4-ALK or other ALK gene translocations
ROS1 Gene Fusion	Negative (No fusion detected)	Positive for CD74-ROS1 or alternative ROS1 gene fusions
KRAS Gene Status	Wild-type (No mutation detected)	Activating mutations such as G12C, G12D, G12V, or G13D
BRAF Gene Status	Wild-type (No mutation detected)	Presence of V600E mutation or non-V600E activating mutations
MET Gene Status	Normal copy number; intact splicing	MET Exon 14 skipping mutation or MET gene amplification
RET Gene Status	Negative (No fusion detected)	Positive for KIF5B-RET or other RET gene fusions
NTRK1/2/3 Gene Status	Negative (No fusion detected)	Presence of NTRK1, NTRK2, or NTRK3 oncogenic fusions
HER2 (ERBB2) Status	Wild-type; normal copy number	HER2 exon 20 insertions, point mutations, or gene amplification

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Sentis Lung Cancer Tissue Outsource Genetech?

• Experienced Healthcare Professionals: Chughtai Lab’s pathology team includes highly trained histopathologists and molecular biologists who oversee specimen adequacy and clinical correlation.
• Patient-Focused Care: The organization prioritizes patient convenience, offering dedicated support desks to guide families through the complex process of molecular testing.
• Quality Diagnostic Services: Chughtai Lab adheres to strict international quality control standards, ensuring that tissue specimens are handled with the utmost care.
• Professional Reporting: Reports are structured clearly, detailing detected mutations and aligning them with internationally recognized therapeutic guidelines for oncologists.
• Modern Diagnostic Approach: By partnering with leading specialized laboratories like Genetech, Chughtai Lab brings advanced global diagnostic technologies to patients in Pakistan.
• Comfortable Environment: Collection centers across the country provide a professional, welcoming, and efficient environment for sample submission and consultation.
• Convenient Location Network: With hundreds of locations across major cities in Pakistan, patients can easily submit samples and receive guidance close to home.
• Commitment to Accurate Diagnosis: Chughtai Lab’s robust logistics network ensures that temperature-sensitive tissue blocks are transported safely, preserving sample integrity for precise analysis.